Evotec announced a major restructuring that includes eliminating up to 800 positions—about one‑sixth of its global workforce—and closing four facilities across Europe and the U.S. The company said the moves, part of an initiative called 'Horizons,' aim to concentrate scientific expertise into centralized 'Centers of Excellence,' reduce operating costs, and sharpen focus on high‑value discovery and preclinical services. The reorganization affects sites spanning Abingdon (UK), Framingham (MA), Lyon (France) and Munich (Germany) and will be implemented over the next two years. Evotec said core hubs in Hamburg, Princeton, Seattle and other locations will remain, while the company seeks to streamline its service footprint to better meet client demands. Customers, partners and employees will monitor the transition closely for continuity of service, especially given Evotec’s role supporting major pharma and hundreds of biotech collaborations.